Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial | ||
| Avicenna Journal of Phytomedicine | ||
| مقاله 6، دوره 8، شماره 6، بهمن و اسفند 2018، صفحه 513-523 اصل مقاله (593.91 K) | ||
| نوع مقاله: Original Research Article | ||
| شناسه دیجیتال (DOI): 10.22038/ajp.2018.28835.2020 | ||
| نویسندگان | ||
| Mansoor Shakiba1؛ Ehsan Moazenzadeh2؛ Ahmad Ali Noorbala1؛ Morteza Jafarinia1؛ Parisa Divsalar1؛ Ladan Kashani3؛ Nazila Shahmansouri1؛ Abbas Tafakhori4؛ Hannaneh Bayat2؛ Shahin Akhondzadeh* 2 | ||
| 1Psychosomatic Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran | ||
| 2Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran | ||
| 3Infertility Ward, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran | ||
| 4Neurology Ward, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran | ||
| چکیده | ||
| Objective: Saffron was found efficient and safe in treatment of neuropsychiatric disorders, in particular depression. We compared the efficacy of saffron with duloxetine in treatment of patients with fibromyalgia. Materials and Methods: In this double-blind parallel-group clinical trial, outpatients with fibromyalgia were randomized to receive either saffron 15 mg or duloxetine 30 mg starting with 1 capsule per day in the first week followed by 2 capsules per day from week 2 until the end of week 8. Participants were men and women aged 18-60 years diagnosed with fibromyalgia based on the American College of Rheumatology 2010 criteria who also had a pain score ≥40 based on visual analogue scale. Participants were excluded in case they had rheumatologic diseases, inflammatory/infectious/autoimmune arthritis, comorbid neuropsychiatric disorders except depressive disorders, pain due to traumatic injuries, drug history of duloxetine or saffron use, current use of psychoactive medications, recent use of muscle relaxants, steroids, opioid analgesics, benzodiazepines, anti-epileptics, or injective analgesics. Primary outcomes included differences in mean score changes from baseline to endpoint between the treatment arms for Hamilton Rating Scale for Depression, Fibromyalgia Impact Questionnaire, and Brief Pain Inventory. Results: Socio-demographic characteristics and baseline scores were similarly distributed between the two treatment arms (2n=46). No significant difference was detected for any of the scales neither in terms of score changes from baseline to endpoint between the two treatment arms (Mean score changes: -4.26 to 2.37; p-values: 0.182-0.900) nor in terms of time´treatment interactions (p-values: 0.209-0.964). Conclusions: Saffron and duloxetine demonstrated comparable efficacy in treatment of fibromyalgia symptoms. | ||
| کلیدواژهها | ||
| Crocus sativus؛ Depression؛ Duloxetine؛ Fibromyalgia؛ Saffron | ||
| مراجع | ||
|
Ablin JN, Häuser W. 2016. Fibromyalgia syndrome: novel therapeutic targets. Pain Manag, 6: 371-381.
Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi A-H, Khalighi-Cigaroudi F. 2004. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med, 4: 12.
American Psychiatric Association. 2000. DSM-IV-TR: Diagnostic and statistical manual of mental disorders, text revision. APA Publishing, Washington, DC.
Amin B, Hosseini S, Hosseinzadeh H. 2017. Enhancement of Antinociceptive Effect by Co-administration of Amitriptyline and Crocus sativus in a Rat Model of Neuropathic Pain. Iran J Pharm Res, 16: 187-200.
Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, Hassanzadeh E, Forghani S, Akhondzadeh S. 2013. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacol, 225:51-9.
Basti AA, Moshiri E, Noorbala A-A, Jamshidi A-H, Abbasi SH, Akhondzadeh S. 2007. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry, 31: 439-442.
Becker S, Schweinhardt P. 2012. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat, 741746.
Burckhardt CS, Clark SR, Bennett RM. 1991. The fibromyalgia impact questionnaire: development and validation. J Rheumatol, 18: 728-733.
Calandre EP, Rico-Villademoros F, Slim M. 2015. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother, 16: 1347-1368.
Carlsson AM. 1983. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain, 16: 87-101.
Chinn S, Caldwell W, Gritsenko K. 2016. Fibromyalgia pathogenesis and treatment options update. Curr Pain Headache Rep, 20: 25.
Cleeland CS, Ryan KM. 1994. The Brief Pain Inventory. Ann Acad Med Singapore, 23: 129-138.
Cordero MD, de Miguel M, Carmona-López I, Bonal P, Campa F, Moreno-Fernández AM. 2010. Oxidative stress and mitochondrial dysfunction in fibromyalgia. Neuro Endocrinol Lett, 31: 169-173.
De Souza Nascimento S, DeSantana JM, Nampo FK, Ribeiro ÊA, da Silva DL, Araújo-Júnior JX, da Silva Almeida JR, Bonjardim LR, de Souza Araújo AA, Quintans-Júnior LJ. 2013. Efficacy and safety of medicinal plants or related natural products for fibromyalgia: a systematic review. Evid Based Complement Alternat Med, 149468.
Ghajar A, Neishabouri SM, Velayati N, Jahangard L, Matinnia N, Haghighi M, Ghaleiha A, Afarideh M, Salimi S, Meysamie A, Akhondzadeh S. 2017. Crocus sativus L. versus Citalopram in the treatment of major depressive disorder with anxious distress: A double-blind, controlled clinical trial. Pharmacopsychiatry, 50: 152-160.
Ghavidel-Parsa B, Amir Maafi A, Haghdoost A, Arabi Y, Khojamli M, Chatrnour G, Bidari A. 2014. The validity and reliability of the Persian version of the Revised Fibromyalgia Impact Questionnaire. Rheumatol Int, 34: 175-180.
Ghavidel-Parsa B, Bidari A, Amir Maafi A, Ghalebaghi B. 2015. The iceberg nature of fibromyalgia burden: the clinical and economic aspects. Korean J Pain, 28: 169-176.
Gracely RH, Ceko M, Bushnell MC. 2012. Fibromyalgia and depression. Pain Res Treat, 486590.
Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry, 23: 56-62.
Hausenblas HA, Saha D, Dubyak PJ, Anton SD. 2013. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med, 11: 377-383.
Häuser W, Petzke F, Sommer C. 2010. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain, 11: 505-521.
Häuser W, Urrútia G, Tort S, Üçeyler N, Walitt B. 2013. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev, CD010292.
Häuser W, Henningsen P. 2014a. Fibromyalgia syndrome: a somatoform disorder? Eur J Pain, 18: 1052-1059.
Häuser W, Walitt B, Fitzcharles M-A, Sommer C. 2014b. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther, 16: 201.
Hewlett S, Dures E, Almeida C. 2011. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi‐Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for Severity, Effect, and Coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue)(FACIT‐F), Multi‐Dimensional Assessment of Fatigue (MAF), Multi‐Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi‐Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF‐36 VT), and Visual Analog Scales (VAS). Arthritis Care Res, 63: S263-S286.
Kashani L, Raisi F, Saroukhani S, Sohrabi H, Modabbernia A, Nasehi AA, Jamshidi A, Ashrafi M, Mansouri P, Ghaeli P, Akhondzadeh S. 2013. Saffron for treatment of fluoxetine‐induced sexual dysfunction in women: randomized double‐blind placebo‐controlled study. Hum Psychopharmacol, 28: 54-60.
Kashani L, Eslatmanesh S, Saedi N, Niroomand N, Ebrahimi M, Hosseinian M, Foroughifar T, Salimi S, Akhondzadeh S. 2017. Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial. Pharmacopsychiatry, 50: 64-68.
Kashani L, Eslatmanesh S, Eftekhari F, Salimi S, Foroughifar T, Etesam F, Safiaghdam H, Moazen-Zadeh E, Akhondzadeh S. 2018. Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial. Arch Gynecol Obstet, 297: 717-724.
Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, Tsatsakis AM. 2015. The effects of Crocus sativus (saffron) and its constituents on nervous system: A review. Avicenna J Phytomed, 5: 376-391.
Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M, Akhondzadeh S. 2014. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res, 215(3):540-6.
Lauche R, Cramer H, Häuser W, Dobos G, Langhorst J. 2015. A systematic overview of reviews for complementary and alternative therapies in the treatment of the fibromyalgia syndrome. Evid Based Complement Alternat Med, 610615.
Lawson K. 2016. Potential drug therapies for the treatment of fibromyalgia. Expert Opin Investig Drugs, 25: 1071-1081.
Lopresti AL, Drummond PD. 2014. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol, 29: 517-527.
Luciano JV, Forero CG, Cerdà-Lafont M, Peñarrubia-María MT, Fernández-Vergel R, Cuesta-Vargas AI, Ruíz JM, Rozadilla-Sacanell A, Sirvent-Alierta E, Santo-Panero P, García-Campayo J. 2016. Functional Status, Quality of Life, and Costs Associated With Fibromyalgia Subgroups. Clin J Pain, 32: 829-840.
Maletic V, Raison CL. 2009. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci, 14: 5291-5338.
Mazidi M, Shemshian M, Mousavi SH, Norouzy A, Kermani T, Moghiman T, Sadeghi A, Mokhber N, Ghayour-Mobarhan M, Ferns GA. 2016. A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression. J Complement Integr Med, 13: 195-199.
Meeus M, Nijs J, Hermans L, Goubert D, Calders P. 2013. The role of mitochondrial dysfunctions due to oxidative and nitrosative stress in the chronic pain or chronic fatigue syndromes and fibromyalgia patients: peripheral and central mechanisms as therapeutic targets? Expert Opin Ther Targets, 17: 1081-1089.
Milajerdi A, Bitarafan V, Mahmoudi M. 2015. A review on the effects of saffron extract and its constituents on factors related to neurologic, cardiovascular and gastrointestinal diseases. J Med Plants, 3: 9-28.
Moazen-Zadeh E, Abbasi SH, Safi-Aghdam H, Shahmansouri N, Arjmandi-Beglar A, Hajhosseinn Talasaz A, Salehiomran A, Forghani S, Akhondzadeh S. 2018. Effects of Saffron on Cognition, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Double-Blind Placebo-Controlled Trial. J Altern Complement Med, 24: 361-368.
Modabbernia A, Sohrabi H, Nasehi AA, Raisi F, Saroukhani S, Jamshidi A, Tabrizi M, Ashrafi M, Akhondzadeh S. 2012. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacol, 223: 381-388.
Moshiri M, Vahabzadeh M, Hosseinzadeh H. 2015. Clinical applications of saffron (Crocus sativus) and its constituents: a review. Drug Res, 65: 287-295.
Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. 2005. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol, 97: 281-284.
Pae CU, Luyten P, Marks DM, Han C, Park SH, Patkar AA, Masand PS, Van Houdenhove B. 2008. The relationship between fibromyalgia and major depressive disorder: a comprehensive review. Curr Med Res Opin, 24: 2359-2371.
Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S. 2013. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol, 33(3):336-42.
Queiroz LP. 2013. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep, 17: 356.
Sadreddini S, Molaeefard M, Noshad H, Ardalan M, Asadi A. 2008. Efficacy of Raloxifen in treatment of fibromyalgia in menopausal women. Eur J Intern Med, 19: 350-355.
Safakhah HA, Taghavi T, Rashidy-Pour A, Vafaei AA, Sokhanvar M, Mohebbi N, Rezaei-Tavirani M. Effects of saffron (Crocus sativus L.) stigma extract and its active constituent crocin on neuropathic pain responses in a rat model of chronic constriction injury. Iran J Pharm Res, 15: 253-261.
Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. 2011. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol, 21: 841-860.
Schmidt-Wilcke T, Clauw DJ. 2011. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol, 7: 518-527.
Schumi J, Wittes JT. 2011. Through the looking glass: understanding non-inferiority. Trials, 12: 106.
Shahmansouri N, Farokhnia M, Abbasi SH, Kassaian SE, Tafti AA, Gougol A, Yekehtaz H, Forghani S, Mahmoodian M, Saroukhani S, Arjmandi-Beglar A. 2014. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord, 155: 216-222.
Sluka KA, Clauw DJ. 2016. Neurobiology of fibromyalgia and chronic widespread pain. Neurosci, 338: 114-129.
Theoharides TC, Tsilioni I, Arbetman L, Panagiotidou S, Stewart JM, Gleason RM, Russell IJ. 2015. Fibromyalgia syndrome in need of effective treatments. J Pharmacol Exp Ther, 355: 255-263.
Thiagarajah AS, Guymer EK, Leech M, Littlejohn GO. 2014. The relationship between fibromyalgia, stress and depression. Int J Clin Rheumatol, 9: 371-384.
Üçeyler N, Sommer C, Walitt B, Häuser W. 2013. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev, CD010782.
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. 2010. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res, 62: 600-610.
Zigmond AS, Snaith RP. 1983. The hospital anxiety and depression scale. Acta Psychiatr Scand, 67: 361-370. | ||
|
آمار تعداد مشاهده مقاله: 28,775 تعداد دریافت فایل اصل مقاله: 12,468 |
||